
Sign up to save your podcasts
Or
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Imran Kausar, Founder of DeepHealth Consulting.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Imran, covering:
Imran Kausar is a visionary healthcare and life sciences leader, blending medical expertise with strategic foresight. A medical doctor by training, Imran specialized in anesthesia and critical care before transitioning to the pharmaceutical industry. Having launched five rare disease medicines and spearheaded innovative work in gene therapies like Zolgensma and Luxturna across Europe, Imran has earned his reputation as a trailblazer in the industry.
As the founder of DeepHealth Consulting, Imran leads the flagship program DeepHealth Futures, which equips life sciences teams to navigate the transformative forces of AI, longevity science, and precision medicine.With nearly two decades of experience in medicine, medical affairs, and general management, Imran’s career spans the cutting edge of rare diseases, antisense oligonucleotides, and healthcare transformation.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
5
3232 ratings
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Imran Kausar, Founder of DeepHealth Consulting.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Imran, covering:
Imran Kausar is a visionary healthcare and life sciences leader, blending medical expertise with strategic foresight. A medical doctor by training, Imran specialized in anesthesia and critical care before transitioning to the pharmaceutical industry. Having launched five rare disease medicines and spearheaded innovative work in gene therapies like Zolgensma and Luxturna across Europe, Imran has earned his reputation as a trailblazer in the industry.
As the founder of DeepHealth Consulting, Imran leads the flagship program DeepHealth Futures, which equips life sciences teams to navigate the transformative forces of AI, longevity science, and precision medicine.With nearly two decades of experience in medicine, medical affairs, and general management, Imran’s career spans the cutting edge of rare diseases, antisense oligonucleotides, and healthcare transformation.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
7,909 Listeners
22,074 Listeners
676 Listeners
2,317 Listeners
122 Listeners
318 Listeners
2,969 Listeners
9,207 Listeners
88 Listeners
29 Listeners
18 Listeners
352 Listeners
1,619 Listeners
0 Listeners
6,572 Listeners